Cynomolgus TNFRSF11B Protein

13.03.2013

Sino Biological Inc. liefert Cynomolgus TNFRSF11B Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Cynomolgus TNFRSF11B Protein lesen Sie bitte: http://www.sinobiological.com/TNFRSF11B-Protein-g-10584.html

Produkt-Information von TNFRSF11B Protein

Synonym	TNFRSF11B
Protein Construction	A DNA sequence encoding the cynomolgus TNFRSF11B (F7G7U5) (Met28-Leu428) was expressed with the Fc region of human IgG1 at the C-terminus.
Source	Cynomolgus
Expression Host	Human Cells

QC Testing von TNFRSF11B Protein

Purity	> 90 % as determined by SDS-PAGE	SDS-PAGE: TNFRSF11B protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Glu 49
Molecular Mass	The recombinant cynomolgus TNFRSF11B is a disulfide-linked homodimer. The reduced monomer comprises 621 amino acids and has a calculated molecular mass of 65 KDa.The apparent molecular mass of the protein is approximately 97 KDa respectively in SDS-PAGE.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von TNFRSF11B Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Beschreibung von TNFRSF11B Protein

Tumor necrosis factor receptor superfamily member 11B, also known as Osteoprotegerin, Osteoclastogenesis inhibitory factor and TNFRSF11B, is a secreted protein. TNFRSF11B contains two death domains and four TNFR-Cys repeats. TNFRSF11B is highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. It is detected at very low levels in brain, placenta and skeletal muscle. It is highly expressed in fetal kidney, liver and lung. TNFRSF11B acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. It inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. TNFRSF11B may also play a role in preventing arterial calcification. It may act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood.

References

Simonet W.S. et al., 1997, Cell. 89: 309-19.
Yasuda H. et al., 1998, Endocrinology. 139: 1329-37.
Ota T. et al., 2004, Nat Genet. 36: 40-5.
Zhang Z. et al., 2004, Protein Sci. 13: 2819-24.

Cytokine